Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 30;23(13):7322.
doi: 10.3390/ijms23137322.

The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation

Alessandra Bearz  1 , Elisa De Carlo  1 , Alessandro Del Conte  1 , Michele Spina  1 , Valentina Da Ros  1 , Elisa Bertoli  1   2 , Alberto Revelant  3 , Brigida Stanzione  1 , Umberto Tirelli  4
Affiliations
Review

The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation

Alessandra Bearz et al. Int J Mol Sci. .

Abstract

The severe prognosis linked with a lung cancer diagnosis has changed with the discovery of oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated advanced lung cancer is the most interesting model, having achieved the longest overall survival. Here, we report the most important paradigmatic shifts in the prognosis and treatment for this subgroup population occurred among lung cancer.

Keywords: ALK; NSCLC; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Alternative splicing leads to several variants of EML4–ALK fusion gene.
Figure 2
Figure 2
Regulative approval timelines of ALK TKIs, in first-line and second-line settings.
Figure 3
Figure 3
ALK inhibitors have different resistance profiles: highlighted in red is the efficacy of several ALK TKIs against the aggressive resistance mutation G1202R; in vitro data (modified from [37]).
Figure 4
Figure 4
Different therapeutic strategies in the management of advanced ALK-positive NSCLC, according to pattern and site of progression.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Yang P., Allen M.S., Aubry M.C., Wampfler J.A., Marks R.S., Edell E.S., Thibodeau S., Adjei A.A., Jett J., Deschamps C. Clinical Features of 5,628 Primary Lung Cancer Patients: Experience at Mayo Clinic From 1997 to 2003. Yearb. Pulm. Dis. 2007;2007:102–104. doi: 10.1016/S8756-3452(08)70346-3. - DOI - PubMed
    1. Society A.C. Lung Cancer Survival Rates. [(accessed on 1 May 2022)]. Available online: https://www.Cancer.Org/Cancer/Lung-Cancer/Detection-Diagnosis-Staging/Su....
    1. Wild C.P., Weiderpass E., Stewart B.V. World Cancer Report: Cancer Research for Cancer Prevention. International Agency for research on cancer; Lyon, France: 2020.
    1. Travis W.T. Lung cancer Pathology: Current concepts. Clin. Chest Med. 2020;41:67–85. doi: 10.1016/j.ccm.2019.11.001. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources